Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

Histologic Predictors of Recurrence in Mucinous Appendiceal Tumors with Peritoneal Dissemination after HIPEC.

Reghunathan M, Kelly KJ, Valasek MA, Lowy AM, Baumgartner JM.

Ann Surg Oncol. 2018 Mar;25(3):702-708. doi: 10.1245/s10434-017-6310-8. Epub 2017 Dec 27.

PMID:
29282599
2.

Prophylactic enoxaparin doses may be inadequate in patients undergoing abdominal cancer surgery.

Baumgartner JM, McKenzie S, Block S, Costantini TW, Lowy AM.

J Surg Res. 2018 Jan;221:183-189. doi: 10.1016/j.jss.2017.08.053. Epub 2017 Sep 25.

PMID:
29229126
3.

Reprogramming pancreatic stellate cells via p53 activation: A putative target for pancreatic cancer therapy.

Saison-Ridinger M, DelGiorno KE, Zhang T, Kraus A, French R, Jaquish D, Tsui C, Erikson G, Spike BT, Shokhirev MN, Liddle C, Yu RT, Downes M, Evans RM, Saghatelian A, Lowy AM, Wahl GM.

PLoS One. 2017 Dec 6;12(12):e0189051. doi: 10.1371/journal.pone.0189051. eCollection 2017.

4.

Clinical Management: Resectable Disease.

White RR, Lowy AM.

Cancer J. 2017 Nov/Dec;23(6):343-349. doi: 10.1097/PPO.0000000000000291.

PMID:
29189330
5.

GPR68, a proton-sensing GPCR, mediates interaction of cancer-associated fibroblasts and cancer cells.

Wiley SZ, Sriram K, Liang W, Chang SE, French R, McCann T, Sicklick J, Nishihara H, Lowy AM, Insel PA.

FASEB J. 2018 Mar;32(3):1170-1183. doi: 10.1096/fj.201700834R. Epub 2018 Jan 3.

PMID:
29092903
6.

Factors Associated with 60-Day Readmission Following Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy.

Kelly KJ, Cajas L, Baumgartner JM, Lowy AM.

Ann Surg Oncol. 2018 Jan;25(1):91-97. doi: 10.1245/s10434-017-6108-8. Epub 2017 Oct 31.

PMID:
29090402
7.

An Intergroup Randomized Phase II Study of Bevacizumab or Cetuximab in Combination with Gemcitabine and in Combination with Chemoradiation in Patients with Resected Pancreatic Carcinoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2204).

Berlin JD, Feng Y, Catalano P, Abbruzzese JL, Philip PA, McWilliams RR, Lowy AM, Benson Iii AB, Blackstock AW.

Oncology. 2018;94(1):39-46. doi: 10.1159/000480295. Epub 2017 Oct 18.

8.

Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, Benson AB 3rd, Binder E, Cardin DB, Cha C, Chiorean EG, Chung V, Czito B, Dillhoff M, Dotan E, Ferrone CR, Hardacre J, Hawkins WG, Herman J, Ko AH, Komanduri S, Koong A, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Scaife C, Thayer S, Weekes CD, Wolff RA, Wolpin BM, Burns J, Darlow S.

J Natl Compr Canc Netw. 2017 Aug;15(8):1028-1061. doi: 10.6004/jnccn.2017.0131.

PMID:
28784865
9.

Molecular Pathways: Targeting the Microenvironment of Liver Metastases.

Milette S, Sicklick JK, Lowy AM, Brodt P.

Clin Cancer Res. 2017 Nov 1;23(21):6390-6399. doi: 10.1158/1078-0432.CCR-15-1636. Epub 2017 Jun 14.

PMID:
28615370
10.

Overinterpretation is common in pathological diagnosis of appendix cancer during patient referral for oncologic care.

Valasek MA, Thung I, Gollapalle E, Hodkoff AA, Kelly KJ, Baumgartner JM, Vavinskaya V, Lin GY, Tipps AP, Hosseini MV, Lowy AM.

PLoS One. 2017 Jun 7;12(6):e0179216. doi: 10.1371/journal.pone.0179216. eCollection 2017.

11.

Hyaluronan-binding peptide for targeting peritoneal carcinomatosis.

Ikemoto H, Lingasamy P, Anton Willmore AM, Hunt H, Kurm K, Tammik O, Scodeller P, Simón-Gracia L, Kotamraju VR, Lowy AM, Sugahara KN, Teesalu T.

Tumour Biol. 2017 May;39(5):1010428317701628. doi: 10.1177/1010428317701628.

12.

Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial.

Chung V, McDonough S, Philip PA, Cardin D, Wang-Gillam A, Hui L, Tejani MA, Seery TE, Dy IA, Al Baghdadi T, Hendifar AE, Doyle LA, Lowy AM, Guthrie KA, Blanke CD, Hochster HS.

JAMA Oncol. 2017 Apr 1;3(4):516-522. doi: 10.1001/jamaoncol.2016.5383.

13.

Safety and Outcome Measures of First-in-Human Intraperitoneal α Radioimmunotherapy With 212Pb-TCMC-Trastuzumab.

Meredith RF, Torgue JJ, Rozgaja TA, Banaga EP, Bunch PW, Alvarez RD, Straughn JM Jr, Dobelbower MC, Lowy AM.

Am J Clin Oncol. 2016 Nov 30. [Epub ahead of print]

PMID:
27906723
14.

Characterization of RON protein isoforms in pancreatic cancer: implications for biology and therapeutics.

Chakedis J, French R, Babicky M, Jaquish D, Mose E, Cheng P, Holman P, Howard H, Miyamoto J, Porras P, Walterscheid Z, Schultz-Fademrecht C, Esdar C, Schadt O, Eickhoff J, Lowy AM.

Oncotarget. 2016 Jul 19;7(29):45959-45975. doi: 10.18632/oncotarget.10009.

15.

Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma.

Fox RG, Lytle NK, Jaquish DV, Park FD, Ito T, Bajaj J, Koechlein CS, Zimdahl B, Yano M, Kopp J, Kritzik M, Sicklick J, Sander M, Grandgenett PM, Hollingsworth MA, Shibata S, Pizzo D, Valasek M, Sasik R, Scadeng M, Okano H, Kim Y, MacLeod AR, Lowy AM, Reya T.

Nature. 2016 Jun 16;534(7607):407-411. doi: 10.1038/nature17988. Epub 2016 Jun 6.

16.

Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101.

Katz MH, Shi Q, Ahmad SA, Herman JM, Marsh Rde W, Collisson E, Schwartz L, Frankel W, Martin R, Conway W, Truty M, Kindler H, Lowy AM, Bekaii-Saab T, Philip P, Talamonti M, Cardin D, LoConte N, Shen P, Hoffman JP, Venook AP.

JAMA Surg. 2016 Aug 17;151(8):e161137. doi: 10.1001/jamasurg.2016.1137. Epub 2016 Aug 17.

17.

Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression.

Kaneda MM, Cappello P, Nguyen AV, Ralainirina N, Hardamon CR, Foubert P, Schmid MC, Sun P, Mose E, Bouvet M, Lowy AM, Valasek MA, Sasik R, Novelli F, Hirsch E, Varner JA.

Cancer Discov. 2016 Aug;6(8):870-85. doi: 10.1158/2159-8290.CD-15-1346. Epub 2016 May 13.

18.

Urokinase-controlled tumor penetrating peptide.

Braun GB, Sugahara KN, Yu OM, Kotamraju VR, Mölder T, Lowy AM, Ruoslahti E, Teesalu T.

J Control Release. 2016 Jun 28;232:188-95. doi: 10.1016/j.jconrel.2016.04.027. Epub 2016 Apr 19.

19.

FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine.

Yeo D, He H, Patel O, Lowy AM, Baldwin GS, Nikfarjam M.

BMC Cancer. 2016 Jan 16;16:24. doi: 10.1186/s12885-016-2057-z.

20.

A Novel Tool for Predicting Major Complications After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.

Baumgartner JM, Kwong TG, Ma GL, Messer K, Kelly KJ, Lowy AM.

Ann Surg Oncol. 2016 May;23(5):1609-17. doi: 10.1245/s10434-015-5012-3. Epub 2015 Dec 17.

21.

Laparoscopy is Safe and Accurate to Evaluate Peritoneal Surface Metastasis Prior to Cytoreductive Surgery.

Marmor RA, Kelly KJ, Lowy AM, Baumgartner JM.

Ann Surg Oncol. 2016 May;23(5):1461-7. doi: 10.1245/s10434-015-4958-5. Epub 2015 Nov 5.

PMID:
26542584
22.

A novel protein isoform of the RON tyrosine kinase receptor transforms human pancreatic duct epithelial cells.

Chakedis J, French R, Babicky M, Jaquish D, Howard H, Mose E, Lam R, Holman P, Miyamoto J, Walterscheid Z, Lowy AM.

Oncogene. 2016 Jun 23;35(25):3249-59. doi: 10.1038/onc.2015.384. Epub 2015 Oct 19.

23.

A tumor-penetrating peptide enhances circulation-independent targeting of peritoneal carcinomatosis.

Sugahara KN, Scodeller P, Braun GB, de Mendoza TH, Yamazaki CM, Kluger MD, Kitayama J, Alvarez E, Howell SB, Teesalu T, Ruoslahti E, Lowy AM.

J Control Release. 2015 Aug 28;212:59-69. doi: 10.1016/j.jconrel.2015.06.009. Epub 2015 Jun 11.

24.

SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma.

Ben-Josef E, Guthrie KA, El-Khoueiry AB, Corless CL, Zalupski MM, Lowy AM, Thomas CR Jr, Alberts SR, Dawson LA, Micetich KC, Thomas MB, Siegel AB, Blanke CD.

J Clin Oncol. 2015 Aug 20;33(24):2617-22. doi: 10.1200/JCO.2014.60.2219. Epub 2015 May 11.

25.

Approach to patients with pancreatic cancer without detectable metastases.

Heestand GM, Murphy JD, Lowy AM.

J Clin Oncol. 2015 Jun 1;33(16):1770-8. doi: 10.1200/JCO.2014.59.7930. Epub 2015 Apr 27. Review.

PMID:
25918279
26.

BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma.

Alakus H, Yost SE, Woo B, French R, Lin GY, Jepsen K, Frazer KA, Lowy AM, Harismendy O.

J Transl Med. 2015 Apr 16;13:122. doi: 10.1186/s12967-015-0485-1.

27.

Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery.

Buckel L, Savariar EN, Crisp JL, Jones KA, Hicks AM, Scanderbeg DJ, Nguyen QT, Sicklick JK, Lowy AM, Tsien RY, Advani SJ.

Cancer Res. 2015 Apr 1;75(7):1376-1387. doi: 10.1158/0008-5472.CAN-14-1931. Epub 2015 Feb 13.

28.

Laparoscopic evacuation of mucinous ascites for palliation of pseudomyxoma peritonei.

Kelly KJ, Baumgartner JM, Lowy AM.

Ann Surg Oncol. 2015 May;22(5):1722-5. doi: 10.1245/s10434-014-4118-3. Epub 2014 Nov 14.

PMID:
25395145
29.

Tumor-penetrating iRGD peptide inhibits metastasis.

Sugahara KN, Braun GB, de Mendoza TH, Kotamraju VR, French RP, Lowy AM, Teesalu T, Ruoslahti E.

Mol Cancer Ther. 2015 Jan;14(1):120-8. doi: 10.1158/1535-7163.MCT-14-0366. Epub 2014 Nov 12.

30.

Enteral stenting for gastric outlet obstruction and afferent limb syndrome following pancreaticoduodenectomy.

Kwong WT, Fehmi SM, Lowy AM, Savides TJ.

Ann Gastroenterol. 2014;27(4):413-417.

31.

A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer.

Schönhuber N, Seidler B, Schuck K, Veltkamp C, Schachtler C, Zukowska M, Eser S, Feyerabend TB, Paul MC, Eser P, Klein S, Lowy AM, Banerjee R, Yang F, Lee CL, Moding EJ, Kirsch DG, Scheideler A, Alessi DR, Varela I, Bradley A, Kind A, Schnieke AE, Rodewald HR, Rad R, Schmid RM, Schneider G, Saur D.

Nat Med. 2014 Nov;20(11):1340-1347. doi: 10.1038/nm.3646. Epub 2014 Oct 19. Erratum in: Nat Med. 2015 Apr;21(4):414.

32.

A hypusine-eIF5A-PEAK1 switch regulates the pathogenesis of pancreatic cancer.

Fujimura K, Wright T, Strnadel J, Kaushal S, Metildi C, Lowy AM, Bouvet M, Kelber JA, Klemke RL.

Cancer Res. 2014 Nov 15;74(22):6671-81. doi: 10.1158/0008-5472.CAN-14-1031. Epub 2014 Sep 26.

33.

Correction: Genome-wide mutational landscape of mucinous carcinomatosis peritonei of appendiceal origin.

Alakus H, Babicky ML, Ghosh P, Yost S, Jepsen K, Dai Y, Arias A, Samuels ML, Mose ES, Schwab RB, Peterson MR, Lowy AM, Frazer KA, Harismendy O.

Genome Med. 2014 Jul 26;6(7):53. doi: 10.1186/s13073-014-0053-y. eCollection 2014. No abstract available.

34.

Long-term outcomes after total pancreatectomy and islet cell autotransplantation: is it a durable operation?

Wilson GC, Sutton JM, Abbott DE, Smith MT, Lowy AM, Matthews JB, Rilo HL, Schmulewitz N, Salehi M, Choe K, Brunner J, Hanseman DJ, Sussman JJ, Edwards MJ, Ahmad SA.

Ann Surg. 2014 Oct;260(4):659-65; discussion 665-7. doi: 10.1097/SLA.0000000000000920.

PMID:
25203883
35.

Borderline resectable pancreatic cancer: definitions and management.

Lopez NE, Prendergast C, Lowy AM.

World J Gastroenterol. 2014 Aug 21;20(31):10740-51. doi: 10.3748/wjg.v20.i31.10740. Review.

36.

Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Baumgartner JM, Tobin L, Heavey SF, Kelly KJ, Roeland EJ, Lowy AM.

Ann Surg Oncol. 2015 May;22(5):1716-21. doi: 10.1245/s10434-014-3985-y. Epub 2014 Aug 22.

PMID:
25145504
37.

Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines.

Tempero MA, Malafa MP, Behrman SW, Benson AB 3rd, Casper ES, Chiorean EG, Chung V, Cohen SJ, Czito B, Engebretson A, Feng M, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Lowy AM, Ma WW, Merchant NB, Mulvihill SJ, Muscarella P 2nd, Nakakura EK, Obando J, Pitman MB, Reddy S, Sasson AR, Thayer SP, Weekes CD, Wolff RA, Wolpin BM, Burns JL, Freedman-Cass DA.

J Natl Compr Canc Netw. 2014 Aug;12(8):1083-93.

PMID:
25099441
38.

The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery.

Prada-Villaverde A, Esquivel J, Lowy AM, Markman M, Chua T, Pelz J, Baratti D, Baumgartner JM, Berri R, Bretcha-Boix P, Deraco M, Flores-Ayala G, Glehen O, Gomez-Portilla A, González-Moreno S, Goodman M, Halkia E, Kusamura S, Moller M, Passot G, Pocard M, Salti G, Sardi A, Senthil M, Spiliotis J, Torres-Melero J, Turaga K, Trout R.

J Surg Oncol. 2014 Dec;110(7):779-85. doi: 10.1002/jso.23728. Epub 2014 Aug 2.

PMID:
25088304
39.

Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727).

Philip PA, Goldman B, Ramanathan RK, Lenz HJ, Lowy AM, Whitehead RP, Wakatsuki T, Iqbal S, Gaur R, Benedetti JK, Blanke CD.

Cancer. 2014 Oct 1;120(19):2980-5. doi: 10.1002/cncr.28744. Epub 2014 Jul 16.

40.

Homozygous GNAS 393C-allele carriers with locally advanced esophageal cancer fail to benefit from platinum-based preoperative chemoradiotherapy.

Alakus H, Bollschweiler E, Hölscher AH, Warnecke-Eberz U, Frazer KA, Harismendy O, Lowy AM, Mönig SP, Eberz PM, Maus M, Drebber U, Siffert W, Metzger R.

Ann Surg Oncol. 2014 Dec;21(13):4375-82. doi: 10.1245/s10434-014-3843-y. Epub 2014 Jul 2.

PMID:
24986238
41.

Genome-wide mutational landscape of mucinous carcinomatosis peritonei of appendiceal origin.

Alakus H, Babicky ML, Ghosh P, Yost S, Jepsen K, Dai Y, Arias A, Samuels ML, Mose ES, Schwab RB, Peterson MR, Lowy AM, Frazer KA, Harismendy O.

Genome Med. 2014 May 29;6(5):43. doi: 10.1186/gm559. eCollection 2014.

42.

The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 Patients with Colorectal Cancer with Peritoneal Carcinomatosis.

Esquivel J, Lowy AM, Markman M, Chua T, Pelz J, Baratti D, Baumgartner JM, Berri R, Bretcha-Boix P, Deraco M, Flores-Ayala G, Glehen O, Gomez-Portilla A, González-Moreno S, Goodman M, Halkia E, Kusamura S, Moller M, Passot G, Pocard M, Salti G, Sardi A, Senthil M, Spilioitis J, Torres-Melero J, Turaga K, Trout R.

Ann Surg Oncol. 2014 Dec;21(13):4195-201. doi: 10.1245/s10434-014-3798-z. Epub 2014 May 23.

PMID:
24854493
43.

An integrin β₃-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition.

Seguin L, Kato S, Franovic A, Camargo MF, Lesperance J, Elliott KC, Yebra M, Mielgo A, Lowy AM, Husain H, Cascone T, Diao L, Wang J, Wistuba II, Heymach JV, Lippman SM, Desgrosellier JS, Anand S, Weis SM, Cheresh DA.

Nat Cell Biol. 2014 May;16(5):457-68. doi: 10.1038/ncb2953. Epub 2014 Apr 20.

44.

Single-incision laparoscopic surgery through an ostomy site: a natural approach by an unnatural orifice.

Lopez NE, Peterson CY, Ramamoorthy SL, McLemore EC, Sedrak MF, Lowy AM, Horgan S, Talamini MA, Sicklick JK.

Surg Laparosc Endosc Percutan Tech. 2015 Feb;25(1):74-8. doi: 10.1097/SLE.0000000000000022.

PMID:
24743670
45.

The RON receptor tyrosine kinase in pancreatic cancer pathogenesis and its potential implications for future targeted therapies.

Kang CM, Babicky ML, Lowy AM.

Pancreas. 2014 Mar;43(2):183-9. doi: 10.1097/MPA.0000000000000088. Review.

46.

Generation of orthotopic patient-derived xenografts from gastrointestinal stromal tumor.

Sicklick JK, Leonard SY, Babicky ML, Tang CM, Mose ES, French RP, Jaquish DV, Hoh CK, Peterson M, Schwab R, Lowy AM.

J Transl Med. 2014 Feb 10;12:41. doi: 10.1186/1479-5876-12-41.

47.

Improved perioperative outcomes with minimally invasive distal pancreatectomy: results from a population-based analysis.

Tran Cao HS, Lopez N, Chang DC, Lowy AM, Bouvet M, Baumgartner JM, Talamini MA, Sicklick JK.

JAMA Surg. 2014 Mar;149(3):237-43. doi: 10.1001/jamasurg.2013.3202.

48.

PI3Kα activates integrin α4β1 to establish a metastatic niche in lymph nodes.

Garmy-Susini B, Avraamides CJ, Desgrosellier JS, Schmid MC, Foubert P, Ellies LG, Lowy AM, Blair SL, Vandenberg SR, Datnow B, Wang HY, Cheresh DA, Varner J.

Proc Natl Acad Sci U S A. 2013 May 28;110(22):9042-7. doi: 10.1073/pnas.1219603110. Epub 2013 May 13.

49.

A dual-color genetically engineered mouse model for multispectral imaging of the pancreatic microenvironment.

Snyder CS, Harrington AR, Kaushal S, Mose E, Lowy AM, Hoffman RM, Bouvet M.

Pancreas. 2013 Aug;42(6):952-8. doi: 10.1097/MPA.0b013e31828643df. Erratum in: Pancreas. 2013 Oct;42(7):1199.

50.

Therapeutic advances in pancreatic cancer.

Paulson AS, Tran Cao HS, Tempero MA, Lowy AM.

Gastroenterology. 2013 Jun;144(6):1316-26. doi: 10.1053/j.gastro.2013.01.078. Review. Erratum in: Gastroenterology. 2013 Sep;145(3):694.

PMID:
23622141

Supplemental Content

Support Center